By Ross Youngs, 
October 10, 2025

White Paper — The Beauty of Microbial Natural Products

Abstract:

For decades, the ‘one‐drug, one‐target’ paradigm shaped discovery strategies. Although this approach yielded many important medicines, it often underperforms against complex, multi‐factorial diseases in which networks of proteins and pathways adapt to single node blockade. Network pharmacology reframes this challenge by embracing polypharmacology—intentional, selective engagement of multiple targets—to achieve more durable efficacy. Polypharmacology is frequently conflated with promiscuous, non‐specific binding. This white paper clarifies that distinction and argues that microbial natural products (NPs), refined by evolution, provide exemplary scaffolds for potent yet selective multi‐target modulation. We review definitions, pitfalls (e.g., PAINS and colloidal aggregation), representative case studies (rapamycin, cyclosporin A, tacrolimus), and enabling technologies (genome/mining, semisynthesis, AI and chemoproteomics). We also correct common statistics: across 1981–2019, ~65% of small‐molecule anticancer drugs are natural product‐derived or inspired when synthetic mimics are included, and about 60% of antibacterials are based on or derived from natural products; for anti‐infectives as a broader class the figure is ~42%. Beyond classic genome-mining and synthetic library screening, we also highlight industrial-scale microbiome mining as a practical route to privileged, stereochemically rich scaffolds that enable selective polypharmacology. Taken together, the evidence supports microbial NPs as privileged starting points for rational, selective polypharmacology rather than promiscuity.

The Challenge of Complex Disease

The classic ‘magic‐bullet’ strategy—maximally selective ligands for single targets—is well suited to simple causal architectures but less effective for diseases driven by robust and redundant networks (e.g., cancer, metabolic and neurodegenerative disorders). When one pathway is blocked, compensatory signaling can restore the disease phenotype. Network pharmacology therefore prioritizes coordinated modulation across multiple nodes to achieve a systems‐level therapeutic effect.

2. Polypharmacology vs. Promiscuity

**Selective polypharmacology** refers to a single molecule engaging multiple, distinct targets through specific, structure‐encoded interactions—akin to a master key designed for several locks. Benefits include: (i) enhanced efficacy through synergy; (ii) reduced resistance via simultaneous pressure on redundant nodes; and (iii) the possibility of built‐in mitigation of on‐target adverse effects. By contrast, **promiscuity** describes non‐specific interactions (often driven by reactivity, redox cycling, colloidal aggregation, or detergent‐like behavior) that produce false positives and unpredictable toxicity. Practical safeguards include substructure filters for PAINS motifs, orthogonal assay formats, inclusion of detergent counterscreens, and aggregation tests.

3. Why Microbial Natural Products Excel

Microbial NPs evolved under intense ecological pressure to secure survival against competitors, predators, and hosts. Their stereochemically rich, three‐dimensional scaffolds occupy regions of chemical space under‐represented in standard synthetic libraries. As a result, they can form high‐fidelity interactions with multiple binding pockets—precisely the profile needed for selective polypharmacology. Across modern approvals (1981–2019), natural‐product‐derived or inspired scaffolds constitute ~65% of small‐molecule anticancer drugs when synthetic mimics are counted, and about 60% of antibacterials are based on or derived from natural products; for the broader anti‐infective class, ~42% are NP‐derived or inspired.

3.1 Discovery at Scale: Industrial Microbiome Mining as a Source of Privileged Scaffolds

Industrial-scale microbiome mining refers to the systematic capture, processing, and multi-omics interrogation of intact, native microbial consortia (environmental or host-associated) at production-relevant scale. Unlike traditional single-strain isolation or in-silico genome mining, this approach preserves community context—the ecological cues, signaling molecules, and stressors that turn on biosynthetic gene clusters and yield complex secondary metabolomes. The result is access to privileged scaffolds—3D-rich, highly decorated chemotypes that recurrently engage families of binding sites with selectivity—well suited to beneficial polypharmacology rather than promiscuity.

What distinguishes industrial-scale microbiome mining:

• Scale & throughput: kilogram-to-ton-scale biomass capture and extraction enables statistically sampling rare taxa and low-abundance metabolites that are invisible to micro-scale workflows.
• Native induction: community-level competition, quorum signaling, and nutrient stress activate otherwise cryptic biosynthetic gene clusters, increasing chemical novelty and complexity.
• Function-first readout: fractionation + high-resolution LC–MS/MS, molecular networking, and target-class phenotypic panels prioritize bioactivity and tractability, not just structural novelty.
• Faster target deconvolution: integrated chemoproteomics, machine learning–guided target inference, and cross-target counterscreens help separate selective polypharmacology from PAINS-like behavior early.

Why this matters for polypharmacology (not promiscuity):

• Microbiome-derived scaffolds are topologically complex (multiple stereocenters, bridged/medium rings, dense H-bonding motifs), which fosters specific multi-target recognition (e.g., orthosteric + allosteric or adjacent pocket engagement) while disfavoring non-specific, surface-adhesive interactions that underlie assay interference.
• Community-conditioned chemistry naturally yields “master-key” scaffolds (e.g., macrocycles, polycyclic lactams, spirocyclic polyketides, NRPS–PKS hybrids) that re-appear as enriched frameworks across unrelated microbiomes—classic “privileged” behavior.

Illustrative workflow (condensed):

1. Sampling at scale (aquatic, soil, host-associated microbiomes) with QA/QC to preserve redox and metabolite integrity.
2. Enrichment & extraction of cell-associated and secreted metabolites under mild conditions to avoid artifactual chemistry.
3. Activity-guided fractionation across a panel of pathway-relevant assays (e.g., inflammasome, lipid handling, synaptic transporters) to detect selective multi-target profiles.
4. De-replication & dereplication by spectral libraries/molecular networking; novelty triage via MS/MS embeddings.
5. Target deconvolution (thermal shift, ABPP/chemoproteomics, CETSA, CRISPR/chemical-genetic interaction maps).
6. Lead-ability filters (PAINS, redox cyclers, aggregators, electrophiles), ADME triage, and early off-target panels to confirm polypharmacology ≠ promiscuity. Thus, these liabilities are screened out early so that selective multi-target activity is not conflated with promiscuity.

4. Case Studies

Several flagship drugs and tool compounds that exemplify selective multi-target modulation originate from complex microbial communities. Industrial-scale microbiome mining generalizes that success by capturing the same ecological pressures that gave rise to scaffolds like macrolides and macrocyclic lactams, thereby increasing the odds of finding master-key chemotypes suitable for network-level intervention.

**Rapamycin (Sirolimus).** A macrolide from *Streptomyces hygroscopicus*. The FKBP12–rapamycin complex binds the FRB domain of mTOR, selectively modulating mTORC1 (and, with chronic exposure in some contexts, mTORC2). This central‐hub targeting drives system‐wide effects relevant to transplantation, oncology, and aging research.

**Cyclosporin A.** A cyclic peptide NP that binds cyclophilin; the drug–immunophilin complex inhibits calcineurin, blocking NFAT‐dependent transcription and producing potent immunosuppression.

**Tacrolimus (FK506).** A macrolide NP that binds FKBP12; the FKBP12–FK506 complex also inhibits calcineurin. Rapamycin and FK506 exemplify small‐molecule ‘molecular glues’ that create composite interfaces to modulate protein function, illustrating how selective multi‐target engagement can be achieved without promiscuity.

5. Development Challenges and Enablers

Key hurdles include supply (low natural titers), structural complexity, and the need for comprehensive target‐deconvolution to separate useful polypharmacology from liability‐driven promiscuity. Enabling strategies include:

• **Genome & metagenome mining** of uncultured microbes and microbiomes.
• **Semisynthesis and analogue design** to tune PK/PD and selectivity.
• **AI‐guided annotation and design** (target prediction; network‐aware screening).
• **Chemoproteomics & thermal‐profiling** to map on‐ and off‐targets in native contexts.

6. Conclusion

Selective polypharmacology is a strength—not a flaw—when it is encoded by evolved chemotypes and verified with rigorous counter‐screening. Microbial NPs remain a privileged starting point for such agents. Integrating NP discovery with genome mining, AI, and modality‐expanding concepts (e.g., molecular glues and targeted protein degradation) should accelerate therapies for oncology, infection, and aging‐related disorders.

References

1. 1. Hopkins, A.L. Network pharmacology: the next paradigm in drug discovery. Nature Chemical Biology 4, 682–690 (2008). https://doi.org/10.1038/nchembio.118
   2. Peters, J.U. Polypharmacology—foe or friend? Journal of Medicinal Chemistry 56, 8955–8971 (2013). https://doi.org/10.1021/jm400856t
   3. Baell, J.B.; Holloway, G.A. New substructure filters for removal of pan‐assay interference compounds (PAINS). Journal of Medicinal Chemistry 53, 2719–2740 (2010). https://doi.org/10.1021/jm901137j
   4. Reddy, A.S.; Zhang, S. Polypharmacology: drug discovery for the future. Expert Review of Clinical Pharmacology 6(1), 41–47 (2013). https://doi.org/10.1586/ecp.12.74
   5. Newman, D.J.; Cragg, G.M. Natural Products as Sources of New Drugs over the Nearly Four Decades from 01/1981 to 09/2019. Journal of Natural Products 83, 770–803 (2020). https://doi.org/10.1021/acs.jnatprod.9b01285
   6. Atanasov, A.G. et al. Natural products in drug discovery: advances and opportunities. Nature Reviews Drug Discovery 20, 200–216 (2021). https://doi.org/10.1038/s41573-020-00114-z
   7. Harvey, A.L.; Edrada‐Ebel, R.; Quinn, R.J. The re‐emergence of natural products for drug discovery in the genomics era. Nature Reviews Drug Discovery 14, 111–129 (2015). https://doi.org/10.1038/nrd4510
   8. Schreiber, S.L. The Rise of Molecular Glues. Cell 184, 3–9 (2021). https://doi.org/10.1016/j.cell.2020.12.020
   9. Blagosklonny, M.V. Rapamycin for longevity: opinion article. Aging (Albany NY) 11, 8048–8067 (2019). https://doi.org/10.18632/aging.102355
   10. Liu, J. et al. Calcineurin is a common target of cyclophilin–cyclosporin A and FKBP– FK506 complexes. Cell 66, 807–815 (1991). https://doi.org/10.1016/0092-8674(91)90124-H
   11. Schreiber, S.L.; Crabtree, G.R. The mechanism of action of cyclosporin A and FK506. Immunology Today 13, 136–142 (1992). https://doi.org/10.1016/0167-5699(92)90111-J
   12. Brown, E.J. et al. A mammalian protein targeted by FKBP12‐rapamycin complex (FRAP/mTOR). Nature 369, 756–758 (1994). https://doi.org/10.1038/369756a0
   13. Sabatini, D.M. et al. RAFT1: a mammalian protein that binds to FKBP12 in a rapamycin‐dependent fashion and is homologous to yeast TORs. Cell 78, 35–43 (1994). https://doi.org/10.1016/0092-8674(94)90570-3
   14. Aylett, C.H.S. et al. Architecture of human mTORC1 and its implication for rapamycin mechanism. eLife 5:e21167 (2016). https://doi.org/10.7554/eLife.21167
   15. Huggins, D.J. et al. Aggregation, colloidal behaviour and false positives in screens. Journal of Medicinal Chemistry 62, 8576–8590 (2019). https://doi.org/10.1021/acs.jmedchem.9b00683
   16. Wolf, T. et al. Towards the sustainable discovery and development of new antibiotics. Nature Reviews Drug Discovery 20, 821–837 (2021). https://doi.org/10.1038/s41573-021-00289-6
   17. Ling, L. L., et al. (2015). A new antibiotic kills pathogens without detectable resistance. Nature, 517, 455–459. (iChip cultivation; teixobactin.)
   18. Milshteyn, A., Schneider, J. S., & Brady, S. F. (2014). Mining the metabiome for natural products. Nat. Prod. Rep., 31, 1183–1201.
   19. Cimermancic, P., et al. (2014). Insights into secondary metabolism from large-scale BGC predictions. Cell, 158, 412–421.
   20. Medema, M. H., & Fischbach, M. A. (2015). Computational approaches to natural product discovery. Nat. Chem. Biol., 11, 639–648.
   21. Donia, M. S., & Fischbach, M. A. (2015). Small molecules from the human microbiota. Science, 349, 1254766.
   22. Katz, L., & Baltz, R. H. (2016). Natural product discovery: past, present, and future. J. Ind. Microbiol. Biotechnol., 43, 155–176.
   23. Medema, M. H., et al. (2021/2023). antiSMASH 6/7: improved BGC detection and comparison. Nucleic Acids Res. (software underpinning genome/mining pipelines).
   24. Paoli, L., et al. (2022). Biosynthetic dark matter: advances in genome mining. Nat. Prod. Rep., 39, 140–162.